Vascepa to Accelerate Lipoprotein Uptake and Elimination: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Vascepa to Accelerate Lipoprotein Uptake and Elimination (NCT03885661), a randomized phase 1 study. The primary outcome is Change in VLDL-apoB100 Production Rate.

2. Clinical Question

This was a mechanistic question about lipid kinetics, rather than a question about clinical events. The outcome focused on production rate during randomized treatment assignment after at least 13 weeks of observation. The study is registered as a Phase 1 trial, and the stated purpose was to help clarify the mechanism of action of icosapent ethyl in statin-treated patients with residual triglyceridemia. The registry record does not report the numerical result needed to determine the direction, magnitude, or precision of the observed treatment contrast.

3. Trial Design

The registry describes a Phase 1, randomized, parallel-group trial with an enrollment of 20. The trial is single-center according to its official title and was conducted by the University of Pennsylvania. Its status is completed. The recorded start date is 2016-01-11, and primary completion is recorded as 2018-08.

Participants were assigned to icosapent ethyl or usual care. Both groups had a statin background. The icosapent ethyl group received a total daily dose of 4 grams, as two 1 gram capsules by mouth twice daily. Usual care is described only as a statin background. Additional information about treatment adherence, dose changes, or other co-interventions is not reported in the registry record.

There is an inconsistency in the registry descriptions of masking: the official title calls the trial open-label, while the masking field records double masking. The registry record does not explain this discrepancy, so the masking status cannot be resolved from the record alone. Randomization is recorded, but the method used to generate or conceal the allocation sequence is not reported in the registry record.

The primary outcome was assessed after at least 13 weeks of observation on randomized treatment assignment. The specified analysis population comprised subjects completing the treatment phase, described as 13-18 weeks. This completion-based population is important when interpreting the outcome: the primary estimand does not, as described, necessarily represent every participant randomized. The registry record does not report participant flow, reasons for non-completion, or how many randomized participants contributed to the primary analysis.

The brief summary frames the trial as a pilot/feasibility mechanistic experiment. Although enrollment and treatment assignment are recorded, the registry record does not report a sample-size justification or describe whether the enrollment target was chosen to support a particular precision or hypothesis-testing objective.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All subjects who completed the ≥ 13 week treatment phase of the study (13-18 weeks).

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in VLDL-apoB100 Production Rate, measured over ≥ 13 weeks of observation on randomized treatment assignment.

The primary endpoint was change in the production rate of very low-density lipoprotein apolipoprotein B100, abbreviated VLDL-apoB100. The unit was mg VLDL apoB100 / kg body weight per day, and the planned summary parameter was the mean with standard deviation as the dispersion measure. The observation timeframe was at least 13 weeks on randomized treatment assignment, with the primary outcome population defined as subjects who completed the 13-18 week treatment phase.

The rate was determined using stable-isotope lipid kinetics based on a primed constant infusion of deuterated leucine. In this mechanistic approach, the measured isotope information is used to estimate the rate at which the specified lipoprotein component is produced. The registry describes the outcome as a way to study lipid changes and clarify the mechanism of action of icosapent ethyl; it is not a clinical event endpoint.

A production-rate endpoint can address a biological process that is not captured simply by a concentration measurement at one time. That makes it relevant to a mechanistic study, while also making the result dependent on the measurement and kinetic-analysis procedures. General interpretation: a difference in a mechanistic measure would describe that measure under the study conditions, not by itself establish a difference in symptoms, cardiovascular events, or other clinical outcomes.

The registry record does not report the group means, standard deviations, change estimates, treatment contrast, confidence interval, or p-value for this endpoint. Therefore, the magnitude and precision of the primary outcome cannot be assessed from the registered result information described in the record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What kind of outcome was measured?

The primary measure was a continuous production rate, expressed as mg VLDL apoB100 / kg body weight per day. The registry specifies the mean as the summary parameter and standard deviation as the dispersion measure. A continuous outcome can take a range of values rather than being limited to categories such as yes or no. For this trial, the measured quantity was not a single lipid concentration but a rate estimated through stable-isotope lipid kinetics.

The outcome description identifies a primed constant infusion of deuterated leucine as the basis for the kinetic technique. The registry does not provide further laboratory or model details. General explanation: a stable-isotope method tracks labeled material through a biological process; measurements over time can then be used to estimate production or turnover. The resulting rate is an estimate from a measurement procedure, rather than a directly observed count of particles produced over a day.

What does a mean and standard deviation describe?

The mean summarizes the central value of a group’s measurements. The standard deviation describes how dispersed individual measurements are around that mean. These answer different questions: the mean concerns the group’s average, while the standard deviation concerns participant-to-participant variability. The standard deviation is not the same as the uncertainty in a treatment comparison. To evaluate uncertainty in a comparison, an analysis would typically report an appropriate standard error or confidence interval, with the exact method depending on the design and analysis.

The registry record does not report group means, standard deviations, or a treatment contrast for the primary measure. It therefore does not permit a numerical comparison of group averages or an assessment of variation in the observed values. The planned choice of a mean and standard deviation does not itself show what the results were.

How does randomization inform the comparison?

Random allocation is intended to make assigned groups comparable, on average, with respect to factors measured and unmeasured before treatment. A parallel-group design means participants are assigned to one group and compared across groups, rather than each participant receiving both conditions in sequence. These design features support a between-group treatment comparison when allocation, follow-up, outcome measurement, and analysis are appropriately carried out.

General explanation: randomization does not guarantee that groups will be identical, particularly in a small trial, and it does not remove the need to report baseline characteristics and participant flow. The registry record describes randomization and a parallel model but does not report the allocation procedure, concealment method, or baseline data. Those aspects of implementation cannot be assessed from the registry record.

What does masking mean in this record?

Masking can reduce the influence of treatment knowledge on behavior, outcome assessment, or decisions during a trial. Here, the official title describes the trial as open-label, while the masking field records double masking. The registry record does not explain which description is accurate or how masking was implemented. That inconsistency should be kept in mind when considering possible sources of bias; it does not establish that any particular bias occurred.

How should statistical precision be understood?

General explanation: an estimate is more informative when accompanied by a measure of uncertainty. A confidence interval gives a range of values compatible with the observed data under the analysis assumptions. A narrow interval indicates greater precision than a wide interval, while neither width nor statistical significance alone determines clinical importance. A p-value, when used, evaluates the data relative to a specified null hypothesis and model. It is not a measure of effect size.

The registry record does not report a confidence interval or p-value for the primary outcome, nor does it provide the outcome estimate needed to judge effect magnitude. The analysis listing alone does not establish which inferential procedure was used. The statistical analysis plan, including model specification and handling of any departures from assumptions, is not reported in the registry record.

Why can variability and model assumptions matter?

General explanation: when outcome variability is greater than assumed by a statistical model, standard errors may be too small and uncertainty may be understated. This is one reason analysts examine the distribution of continuous outcomes and consider whether model assumptions are reasonable. The registry record does not report a distributional assessment or identify a specific model for the primary analysis, so no conclusion about over-dispersion or other model features can be drawn for this trial.

The sample-size planning assumptions described in the record are an illustration based on the observed effect, using a two-sided significance level of 0.05, equal allocation, and a normal approximation. The illustration is not described as the trial’s own design justification. General explanation: planning calculations estimate the enrollment needed for a specified effect and assumptions; they do not measure the power achieved after a trial has been conducted. No numerical planning results or stated effect fractions are reported in the registry record, and no sample-size justification is reported.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists one primary outcome measure and one analysis, but it also indicates that the primary outcome has several categories or time points and was not reduced to one comparison. The record does not describe the categories or time points in more detail, or identify a single numerical contrast for interpretation. A count of analyses alone does not establish that multiplicity was absent: multiple outcome categories, time points, or statistical comparisons can raise multiplicity questions even when only one analysis entry is listed.

General explanation: when several hypotheses are tested, the chance of at least one apparently unusual result can increase. A prespecified testing hierarchy or adjustment procedure can address that issue, depending on the aims. The multiplicity strategy, including whether any adjustment was planned or used, is not reported in the registry record. No multiplicity-adjusted result is reported.

The specified primary outcome population consisted of all subjects who completed the at least 13 week treatment phase, described as 13-18 weeks. The registry record does not report the number who completed, the number with an observed outcome, reasons for missing measurements, or methods for handling missing data. It also does not report whether imputation or a sensitivity analysis was used.

The record does not describe an intention-to-treat analysis population or another analysis set beyond the completion-based population for the primary outcome. It therefore cannot establish how participants who did not complete treatment, or who lacked outcome measurements, were treated in the analysis. These reporting gaps limit assessment of possible attrition bias and of how closely the analyzed population represents the randomized population.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The registry safety information lists serious adverse events separately from other adverse events. In the icosapent ethyl group, the number at risk for serious adverse events was 12, with 0 affected; for other adverse events, 12 were at risk and 8 were affected. In the usual-care group, 8 were at risk for serious adverse events, with 0 affected; for other adverse events, 8 were at risk and 8 were affected. Deaths are recorded as 0 in both groups. No serious adverse event terms are listed.

These are counts as recorded, not estimates of treatment effect. The affected counts for other adverse events do not indicate, by themselves, the nature, severity, timing, duration, or relationship of events to study treatment. The registry record does not provide those details or a statistical comparison of the safety counts. The group sizes at risk are also the denominators recorded for these safety summaries; they should not be assumed to describe the primary-outcome analysis population.

General interpretation: absence of a recorded serious event in a small trial does not establish that the risk of such events is absent. The safety figures describe what was recorded among the participants listed as at risk, and their interpretation is limited by the trial’s size and the detail available in the registry record. They do not, on their own, establish a comparative safety profile.

12. What the Result Does, and Does Not, Mean

This trial addresses a mechanistic question: whether icosapent ethyl, added to a statin background, is associated with a change in VLDL-apoB100 production rate compared with usual care on a statin background. Its stable-isotope outcome is intended to characterize a lipid-production process during randomized treatment. The registry record describes the question and method, but does not report numerical primary outcome results.

As a result, the record does not establish the direction or size of any observed difference, how variable the measurements were, or how precisely a treatment contrast was estimated. A numerical interpretation would require the group summaries or an estimated contrast and its uncertainty. The listed existence of one analysis does not supply those findings. No claim that the intervention increased, decreased, or left production rate unchanged can be drawn from the information in the registry record.

Even if a mechanistic effect estimate were available, its meaning would be bounded by the participants studied, the statin background, the treatment duration, and the kinetic measurement. It would not, by itself, answer whether clinical outcomes changed. The study is described as a Phase 1 pilot/feasibility experiment intended to help clarify a mechanism in statin-treated patients with residual triglyceridemia. The registry record does not report a clinical event outcome for this question.

The primary analysis population is described as treatment-phase completers. Without participant flow and missing-data details, it is not possible to assess whether the completion-based analysis represents all randomized participants. The record also leaves the open-label versus double-masked description unresolved. These are interpretive limits, not proof that the study’s procedures were inadequate.

The most supportable conclusion is about the design and the information reported: a randomized, parallel-group mechanistic trial compared icosapent ethyl with usual care on a statin background, and its primary endpoint was a stable-isotope estimate of VLDL-apoB100 production rate. The registry record does not report the numerical endpoint result or enough statistical detail to judge its magnitude and precision. It therefore cannot settle the treatment-effect question on the basis of the registered results alone.

13. Why This Trial Matters Statistically

The trial illustrates how a clinical study can focus on a biological process rather than a clinical event. VLDL-apoB100 production rate is a kinetic measure, assessed with stable-isotope techniques, and the study’s stated purpose was to help clarify the mechanism of action of icosapent ethyl. Such measures can be useful for examining how a treatment may relate to lipid handling, while requiring care not to extend a mechanistic finding beyond what it measures.

Statistically, the record highlights the distinction between a planned endpoint and a reported result. It gives the outcome definition, unit, summary parameter, dispersion measure, and analysis population, but it does not report the group values or a treatment contrast. Without an estimate and uncertainty measure, readers cannot evaluate effect magnitude or precision. Registration details about design do not replace reporting of the result.

The completion-based primary outcome population also illustrates why analysis populations matter. A result among people who complete the treatment phase can answer a different question from a result that includes everyone randomized. Participant flow and missing-data methods help readers understand that distinction, but they are not reported in the registry record.

Finally, the record contains conflicting masking descriptions and notes that the primary outcome includes several categories or time points not reduced to one comparison. Those details show why transparent reporting of procedures and analysis choices is important. Clear resolution would help readers assess risk of bias, multiplicity, and the scope of the primary inference. The registry record is informative about the mechanistic question and trial structure, but incomplete for judging the numerical treatment result.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most direct limitation for statistical interpretation is that the numerical primary outcome result is not reported in the registry record. There are no group means, standard deviations, treatment contrast, confidence interval, or p-value in the available outcome details. Thus, the primary finding’s magnitude, direction, and precision cannot be assessed.

The analysis population is defined by completion of the treatment phase, lasting 13-18 weeks. The record does not report participant flow, completion counts, reasons for withdrawal, outcome availability, or missing-data handling. Without those details, the impact of incomplete follow-up on the primary analysis cannot be evaluated. The record also does not specify whether a broader randomized population was analyzed.

Masking is unclear because the official title describes an open-label trial and the masking field records double masking. The registry record does not resolve this inconsistency or describe implementation. The randomization method and allocation concealment are also not reported, limiting assessment of how assignment was carried out.

The primary outcome is described as including several categories or time points, but it is not reduced to one comparison. The registry record does not provide further detail about these categories or explain how multiplicity was addressed. The analysis plan, including model choice and assumptions, is not reported. A sample-size justification is not reported; the planning assumptions listed are explicitly an illustration based on the observed effect rather than the trial’s own design.

Finally, this was a Phase 1 pilot/feasibility mechanistic experiment with an enrollment of 20, not a registry report of clinical event outcomes. The record does not provide evidence about clinical effects. The missing outcome statistics and procedural detail constrain interpretation; they do not show what the unreported findings would have been.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Vascepa to Accelerate Lipoprotein Uptake and Elimination — NCT03885661.
• Registry record last updated 2021-11-11; status last verified 2021-10.
• Results first posted 2021-11-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03885661, titled Vascepa to Accelerate Lipoprotein Uptake and Elimination, is a completed Phase 1 randomized, parallel-group trial sponsored by the University of Pennsylvania. The official title describes a single-center mechanistic trial of AMR101 in patients with dyslipidemia. Enrollment is recorded as 20; the start date is 2016-01-11, and primary completion is 2018-08.

The comparison was icosapent ethyl at a total daily dose of 4 grams against usual care, with a statin background in both groups. The primary outcome was change in VLDL-apoB100 production rate, measured using stable-isotope lipid kinetics after at least 13 weeks of randomized treatment assignment. The primary outcome population was treatment-phase completers, described as completing 13-18 weeks.

The registry record does not report numerical primary outcome results or the statistical details needed to assess their precision. It also does not resolve the discrepancy between open-label wording in the official title and the double-masking entry. Safety counts are recorded, including 0 serious adverse events and 0 deaths in both groups, alongside other adverse-event counts. The trial is described as a mechanistic pilot/feasibility study, and its registered details do not establish clinical outcome effects.